<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730403</url>
  </required_header>
  <id_info>
    <org_study_id>16-00090</org_study_id>
    <nct_id>NCT02730403</nct_id>
  </id_info>
  <brief_title>TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051</brief_title>
  <official_title>Treatment-as-Usual (TAU) Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With National Institute on Drug Abuse (NIDA) CTN-0051</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, &quot;ancillary study&quot; intended to describe opioid use among opioid use
      disorder patients following their discharge into the community from inpatient detoxification
      and/or short-term residential treatment programs affiliated with parent study CTN-0051, which
      assessed the comparative effectiveness of extended release injectable naltrexone (XR-NTX,
      Vivitrol®), an opioid antagonist recently approved and indicated for the prevention of
      relapse to opioid dependence, versus buprenorphine-naloxone (BUP-NX, Suboxone®), a high
      affinity partial agonist indicated for maintenance treatment of opioid dependence, as
      pharmacotherapeutic aids to recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participant recruitment will begin after recruitment for CTN-0051 has been completed. Opioid
      use disorder patients will be recruited prior to leaving detoxification and/or short-term
      residential programs. Screening and baseline data (focused on demographics, diagnosis and
      service utilization) will be collected prior to discharge, and follow-up data (focused on
      opioid use) will be collected at weeks 1, 4 and 8 following discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Days of Opioid Use</measure>
    <time_frame>Up to Week 4 Post Discharge</time_frame>
    <description>Days of use during the first 4 weeks post discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Urine Drug Screen (UDS) at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Number of positive UDSs at Week 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative UDSs at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Number of negative UDSs at Week 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Missing UDSs at Week 1</measure>
    <time_frame>week 1</time_frame>
    <description>Number of missing UDSs at Week 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Missing UDSs at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Number of missing UDSs at Week 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive UDSs at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Number of positive UDSs at Week 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative UDSs at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Number of negative UDSs at Week 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Missing UDSs at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Number of missing UDSs at Week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative UDSs at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Number of negative UDSs at Week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive UDSs at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Number of positive UDSs at Week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Use</measure>
    <time_frame>Up to Week 8 Post Discharge</time_frame>
    <description>Days to first opioid use from Timeline Followback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Regular Use</measure>
    <time_frame>Up to Week 8 Post Discharge</time_frame>
    <description>Days to regular opioid use from Timeline Followback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days of Opioid Use</measure>
    <time_frame>Up to Week 8 Post Discharge</time_frame>
    <description>Days of use up 8 weeks post discharge</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">211</enrollment>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>Opioid Use Disorder Patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment As Usual</intervention_name>
    <arm_group_label>Opioid Use Disorder Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be a convenience sample of up to three hundred sixty (360) opioid
        dependent patients leaving detoxification or short-term residential units at sites
        participating in CTN-0051. Up to 60 participants will be recruited at each of approximately
        six sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older;

          -  Meet DSM-5 criteria for opioid-use disorder (heroin or prescription opioids);

          -  Have used opioids other than as specifically prescribed within thirty days prior to
             consent

          -  Seeking treatment for opioid dependence;

          -  Able to provide written informed consent;

          -  Able to speak English sufficiently to understand the study procedures.

        Exclusion Criteria:

          -  Serious medical, psychiatric or substance use disorder that, in the opinion of the
             Site PI, would make participation hazardous to the participant, compromise study
             findings or prevent the participant from completing the study;

          -  Suicidal or homicidal ideation that requires immediate attention;

          -  Maintenance on methadone at doses of 30mg or greater at the time of signing consent;

          -  Presence of pain of sufficient severity as to require ongoing pain management with
             opioids;

          -  Pending legal action or other reasons that might prevent an individual from completing
             the study;

          -  If female, currently pregnant or breastfeeding or planning on conception;

          -  Prior participation in parent trial CTN-0051
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Rotrosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tarzana Treatment Centers</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gateway Community Services, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Street Treatment and Resources</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryhaven</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <results_first_submitted>March 4, 2020</results_first_submitted>
  <results_first_submitted_qc>March 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2020</results_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02730403/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02730403/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment As Usual</title>
          <description>Patients admitted to detoxification or short term residential programs associated with CTN-0051 for Opioid Use Disorder (OUD).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment As Usual</title>
          <description>Patients admitted to detoxification or short term residential programs associated with CTN-0051 with OUD.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 - &lt;25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 - &lt;35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 - &lt;45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 - &lt;55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55 - &lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Opioid Severity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days of Opioid Use</title>
        <description>Days of use during the first 4 weeks post discharge</description>
        <time_frame>Up to Week 4 Post Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Opioid Use</title>
          <description>Days of use during the first 4 weeks post discharge</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive Urine Drug Screen (UDS) at Week 1</title>
        <description>Number of positive UDSs at Week 1</description>
        <time_frame>week 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Urine Drug Screen (UDS) at Week 1</title>
          <description>Number of positive UDSs at Week 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Negative UDSs at Week 1</title>
        <description>Number of negative UDSs at Week 1</description>
        <time_frame>week 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative UDSs at Week 1</title>
          <description>Number of negative UDSs at Week 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Missing UDSs at Week 1</title>
        <description>Number of missing UDSs at Week 1</description>
        <time_frame>week 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Missing UDSs at Week 1</title>
          <description>Number of missing UDSs at Week 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Missing UDSs at Week 4</title>
        <description>Number of missing UDSs at Week 4</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Missing UDSs at Week 4</title>
          <description>Number of missing UDSs at Week 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive UDSs at Week 4</title>
        <description>Number of positive UDSs at Week 4</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive UDSs at Week 4</title>
          <description>Number of positive UDSs at Week 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Negative UDSs at Week 4</title>
        <description>Number of negative UDSs at Week 4</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative UDSs at Week 4</title>
          <description>Number of negative UDSs at Week 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Missing UDSs at Week 8</title>
        <description>Number of missing UDSs at Week 8</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Missing UDSs at Week 8</title>
          <description>Number of missing UDSs at Week 8</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Negative UDSs at Week 8</title>
        <description>Number of negative UDSs at Week 8</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative UDSs at Week 8</title>
          <description>Number of negative UDSs at Week 8</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive UDSs at Week 8</title>
        <description>Number of positive UDSs at Week 8</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive UDSs at Week 8</title>
          <description>Number of positive UDSs at Week 8</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to First Use</title>
        <description>Days to first opioid use from Timeline Followback</description>
        <time_frame>Up to Week 8 Post Discharge</time_frame>
        <population>Patients admitted to detoxification or short term residential programs associated with CTN-0051 for OUD</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use</title>
          <description>Days to first opioid use from Timeline Followback</description>
          <population>Patients admitted to detoxification or short term residential programs associated with CTN-0051 for OUD</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Regular Use</title>
        <description>Days to regular opioid use from Timeline Followback</description>
        <time_frame>Up to Week 8 Post Discharge</time_frame>
        <population>Patients admitted to detoxification or short term residential programs associated with CTN-0051 for OUD</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Regular Use</title>
          <description>Days to regular opioid use from Timeline Followback</description>
          <population>Patients admitted to detoxification or short term residential programs associated with CTN-0051 for OUD</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days of Opioid Use</title>
        <description>Days of use up 8 weeks post discharge</description>
        <time_frame>Up to Week 8 Post Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment As Usual</title>
            <description>Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Opioid Use</title>
          <description>Days of use up 8 weeks post discharge</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 month</time_frame>
      <desc>For purposes of this study, only overdoses (whether hospitalized or not) and all deaths were collected. The relationship of adverse event was only collected for overdose events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment As Usual</title>
          <description>Patients who were admitted to detoxification or short term residential programs associated with CTN-0051 with OUD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Rotrosen</name_or_title>
      <organization>NYU Grossman School of Medicine</organization>
      <phone>646-754-4763</phone>
      <email>john.rotrosen@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

